Citius Oncology (NASDAQ:CTOR) Upgraded to "Hold" at Wall Street Zen

Key Points

• Citius Oncology (NASDAQ: CTOR) has been upgraded to a "hold" rating by Wall Street Zen, following similar downgrades from other analysts such as Maxim Group and Citigroup.
• The company reported a missing EPS of ($0.11) in its latest quarterly earnings, falling short of analysts' estimates of ($0.09).
• A hedge fund, Citadel Advisors LLC, recently purchased 22,699 shares of Citius Oncology, indicating significant institutional interest as 70.52% of the stock is owned by institutional investors.

Citius Oncology (NASDAQ:CTOR - Get Free Report) was upgraded by Wall Street Zen to a "hold" rating in a research note issued on Saturday.

A number of other equities research analysts have also recently issued reports on CTOR. Maxim Group cut shares of Citius Oncology from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 23rd. Citigroup downgraded Citius Oncology to a "hold" rating in a research note on Friday, May 23rd.

Citius Oncology Stock Up 1.0%

CTOR stock opened at $1.97 on Friday. The company has a quick ratio of 0.05, a current ratio of 0.36 and a debt-to-equity ratio of 0.11. The company has a fifty day moving average price of $2.14 and a two-hundred day moving average price of $1.36. Citius Oncology has a one year low of $0.55 and a one year high of $49.00.

Citius Oncology (NASDAQ:CTOR - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02).

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Citius Oncology stock. Citadel Advisors LLC purchased a new stake in Citius Oncology, Inc. (NASDAQ:CTOR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 22,699 shares of the company's stock, valued at approximately $26,000. 70.52% of the stock is owned by institutional investors.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.